Skip to main content
OpenTrials
Completed

NCT Number: NCT06662123

Pharmacokinetic and Safety Study of Subcutaneous and Intravenous Anifrolumab Delivered in Healthy Adult Participants

This is a randomized, Phase I, open-label, single-dose study to evaluate the PK, safety, and tolerability of anifrolumab administered to male and female healthy Chinese participants aged 18 to 55 years. Approximately 24 participants, who fulfill the eligibility criteria, will be administered anifrolumab via SC route or IV route, and participants will be randomized to the two arms in a 1:1 ratio.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Volunteers

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Research Site

Wuhan, 430022, China

About this study

The purpose of this study is to evaluate the PK, safety, and tolerability of a single dose of anifrolumab subcutaneously or intravenously administered to healthy Chinese participants aged 18 to 55 years. The primary study endpoints are PK standard endpoints. The secondary study endpoints are standard endpoints for safety assessment, including adverse events, serious adverse events, and clinical safety laboratory measurements. The participants must abstain from taking prescription or non-prescription drugs (including vitamins and dietary or herbal supplements) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) before the start of study intervention until completion of the follow-up visit, unless, in the opinion of the investigator and sponsor, the medication will not interfere with the study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Able to complete the follow-up visit as required by the protocol.
  • Participant must be 18 to 55 years of age (both inclusive), at the time of signature of the ICF.
  • A body mass index of ≥ 18.5 to ≤ 26.0 kg/m2 and body weight of at least 45 kg for females and 50 kg for males at screening.
  • Capable of giving signed informed consent as described in Appendix A which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Exclusion criteria

  • History of malignancy with some exceptions
  • History of alcohol or drug abuse within the past 2 years.
  • Any significant disease, disorder, or finding that may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data.

Treatment and study plan

Anifrolumab

Drug

Participants will receive a single SC or IV dose of anifrolumab at day 1

Other names: Saphnelo

Primary outcomes

  1. SC and IV Arm: Area under the serum concentration-time curve from the pre-dose concentration extrapolated to infinity (AUCinf)

    Time frame: At predefined intervals throughout the study period (From Day 1 to Day 57)

    The concentration of anifrolumab in serum will be determined (AUCinf will be derived).

  2. SC and IV Arm: Maximum observed serum (peak) concentration (Cmax)

    Time frame: At predefined intervals throughout the study period (From Day 1 to Day 57)

    The concentration of anifrolumab in serum will be determined (Cmax will be derived).

  3. SC and IV Arm: Time to reach peak or maximum observed concentration (tmax)

    Time frame: At predefined intervals throughout the study period (From Day 1 to Day 57)

    The concentration of anifrolumab in serum will be determined (tmax will be derived).

  4. SC and IV Arm: Area under the serum concentration-time curve from pre-dose concentration to time of last quantifiable concentration (AUClast)

    Time frame: At predefined intervals throughout the study period (From Day 1 to Day 57)

    The concentration of anifrolumab in serum will be determined (AUClast will be derived).

  5. SC and IV Arm: half-life associated with the terminal slope of a semi-logarithmic concentration-time curve (t½λz)

    Time frame: At predefined intervals throughout the study period (From Day 1 to Day 57)

    The concentration of anifrolumab in serum will be determined (t½λz will be derived).

  6. Bioavailability (F)

    Time frame: At predefined intervals throughout the study period (From Day 1 to Day 57)

    The concentration of anifrolumab in serum will be determined (F will be derived).

  7. SC Arm: Apparent total body clearance of drug after extravascular administration (CL/F)

    Time frame: At predefined intervals throughout the study period (From Day 1 to Day 57)

    The concentration of anifrolumab in serum will be determined (CL/F will be derived).

  8. SC Arm:Volume of distribution during the terminal phase after extravascular administration (Vz/F)

    Time frame: At predefined intervals throughout the study period (From Day 1 to Day 57)

    The concentration of anifrolumab in serum will be determined (Vz/F will be derived).

  9. IV Arm: volume of distribution during the terminal phase after intravenous administration (Vz)

    Time frame: At predefined intervals throughout the study period (From Day 1 to Day 57)

    The concentration of anifrolumab in serum will be determined (Vz will be derived).

  10. IV Arm: Apparent total body clearance of drug after intravenous administration (CL)

    Time frame: At predefined intervals throughout the study period (From Day 1 to Day 57)

    The concentration of anifrolumab in serum will be determined (CL will be derived).

Secondary outcomes

  1. Adverse Event

    Time frame: From the time of signature of the ICF, throughout the study and including the follow-up period (approximately 12 weeks)

    Assessments related to AEs cover

    • Occurrence/frequency
    • Relationship to study intervention as assessed by investigator
    • Intensity
    • Seriousness
    • Death
    • AEs leading to discontinuation of study intervention
    • AESI

  2. Vital Signs of blood pressure

    Time frame: From the time of signature of the ICF, throughout the study and including the follow-up period (approximately 12 weeks)

    • Observed value
    • Absolute change from baseline values over time
    • Vital sign status including change in abnormality (eg, low, normal, high) from baseline to minimum/maximum postbaseline value
    • Treatment-emergent changes outside predefined criteria

  3. 12-lead ECG measurements include heart rate, RR interval, PR interval, QRS duration, and QT interval

    Time frame: From the time of signature of the ICF, throughout the study and including the follow-up period (approximately 12 weeks)

    Assessments related to ECG cover:

    • Observed value
    • Absolute change from baseline values over time
    • ECG reading at baseline and each scheduled visit (normal, abnormal - clinically not significant, abnormal - clinically significant) including shifts in ECG interpretation compared to baseline
    • Treatment-emergent changes outside predefined criteria

  4. Safety haematology laboratory parameters: WBC, Neutrophils absolute count, RBC, Lymphocytes absolute count, Hb, Monocytes absolute count, HCT, Eosinophils absolute count, MCV, Basophils absolute count, MCH, Platelets, MCHC, Reticulocytes absolute count

    Time frame: From the time of signature of the ICF, throughout the study and including the follow-up period (approximately 12 weeks)

    Assessments related to clinical laboratory safety

    • Observed value
    • Absolute change from baseline values over time
    • Laboratory status including change in abnormality (eg, low, normal, high) from baseline to minimum and maximum postbaseline value
    • Treatment-emergent changes in laboratory parameters outside predefined criteria Urinalysis categorisation as collected in the database including change in categorisation from baseline to the last post-baseline value.

  5. Physical examination of height

    Time frame: From the time of signature of the ICF, throughout the study and including the follow-up period (approximately 12 weeks)

    Any new or aggravated clinically relevant abnormal medical finding at a physical examination as compared with the baseline assessment will be reported as an AE unless unequivocally related to the disease under study.

  6. Vital Signs of pulse rate

    Time frame: From the time of signature of the ICF, throughout the study and including the follow-up period (approximately 12 weeks)

    • Observed value
    • Absolute change from baseline values over time
    • Vital sign status including change in abnormality (eg, low, normal, high) from baseline to minimum/maximum postbaseline value
    • Treatment-emergent changes outside predefined criteria

  7. Vital Signs of body temperature

    Time frame: From the time of signature of the ICF, throughout the study and including the follow-up period (approximately 12 weeks)

    • Observed value
    • Absolute change from baseline values over time
    • Vital sign status including change in abnormality (eg, low, normal, high) from baseline to minimum/maximum postbaseline value
    • Treatment-emergent changes outside predefined criteria

  8. Vital Signs of respiratory rate

    Time frame: From the time of signature of the ICF, throughout the study and including the follow-up period (approximately 12 weeks)

    • Observed value
    • Absolute change from baseline values over time
    • Vital sign status including change in abnormality (eg, low, normal, high) from baseline to minimum/maximum postbaseline value
    • Treatment-emergent changes outside predefined criteria

  9. Safety clinical chemistry laboratory parameters: Sodium, CRP, Potassium, ALP, Urea, ALT, Creatinine, AST, Albumin, GGT, Calcium, TBL, Phosphate, Conjugated bilirubin, Glucose, Creatine kinase

    Time frame: From the time of signature of the ICF, throughout the study and including the follow-up period (approximately 12 weeks)

    Assessments related to clinical laboratory safety

    • Observed value
    • Absolute change from baseline values over time
    • Laboratory status including change in abnormality (eg, low, normal, high) from baseline to minimum and maximum postbaseline value
    • Treatment-emergent changes in laboratory parameters outside predefined criteria Urinalysis categorisation as collected in the database including change in categorisation from baseline to the last post-baseline value.

  10. Safety urinalysis laboratory parameters: Glucose Protein, Blood, Microscopy (if positive for protein or blood)

    Time frame: From the time of signature of the ICF, throughout the study and including the follow-up period (approximately 12 weeks)

    Assessments related to clinical laboratory safety

    • Observed value
    • Absolute change from baseline values over time
    • Laboratory status including change in abnormality (eg, low, normal, high) from baseline to minimum and maximum postbaseline value
    • Treatment-emergent changes in laboratory parameters outside predefined criteria Urinalysis categorisation as collected in the database including change in categorisation from baseline to the last post-baseline value.

  11. Physical examination of weight

    Time frame: From the time of signature of the ICF, throughout the study and including the follow-up period (approximately 12 weeks)

    Any new or aggravated clinically relevant abnormal medical finding at a physical examination as compared with the baseline assessment will be reported as an AE unless unequivocally related to the disease under study.

  12. Physical examination of general appearance, the lungs, cardiovascular system, and the abdomen

    Time frame: From the time of signature of the ICF, throughout the study and including the follow-up period (approximately 12 weeks)

    Any new or aggravated clinically relevant abnormal medical finding at a physical examination as compared with the baseline assessment will be reported as an AE unless unequivocally related to the disease under study.

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

A Randomized, Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Subcutaneously and Intravenously Delivered Anifrolumab in Healthy Chinese Participants

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Oct 28, 2024
Registry last updated
Mar 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.